Tuberculosis vaccines in clinical trials
- 1 May 2011
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Vaccines
- Vol. 10 (5), 645-658
- https://doi.org/10.1586/erv.11.28
Abstract
Effective prophylactic and/or therapeutic vaccination is a key strategy for controlling the global TB epidemic. The partial effectiveness of the existing TB vaccine, bacille Calmette–Guérin (BCG), suggests effective vaccination is possible and highlights the need for an improved vaccination strategy. Clinical trials are evaluating both modifications to the existing BCG immunization methods and also novel TB vaccines, designed to replace or boost BCG. Candidate vaccines in clinical development include live mycobacterial vaccines designed to replace BCG, subunit vaccines designed to boost BCG and therapeutic vaccines designed as an adjunct to chemotherapy. There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen.Keywords
This publication has 139 references indexed in Scilit:
- Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cellsEuropean Journal of Immunology, 2009
- Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell responseVaccine, 2009
- Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnosticsProceedings of the National Academy of Sciences of the United States of America, 2009
- New Insights on Adenovirus as Vaccine VectorsMolecular Therapy, 2009
- Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primatesVaccine, 2009
- Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysProceedings of the National Academy of Sciences of the United States of America, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human VolunteersThe Journal of Infectious Diseases, 2008
- Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South AfricaThe Journal of Infectious Diseases, 2008
- Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populationsEuropean Journal of Immunology, 2007